��<!DOCTYPE html> <html> <head> <title></title> <link rel="stylesheet" href="jquery.mobile-1.0a4.1.css" /> <link rel="stylesheet" href="Common.css" /> <script src="jquery-1.5.2.min.js"></script> <script src="jquery.mobile-1.0a4.1.js"></script> <link href='https://fonts.googleapis.com/css?family=Open+Sans' rel='stylesheet' type='text/css'> <style type="text/css"> body {font-family: 'Open Sans', sans-serif;} </style> </head> <body> <div data-role="page"> <style type="text/css"> table { width: 100%; } table caption { text-align: left; } table thead th { text-align: left; } table td { text-align: left; padding: 6px; width: 100%; border-bottom-style: ridge; border-bottom-width: thin; border-bottom-color: Gray; } table th { text-align: left; padding: 6px; white-space: nowrap; border-bottom-style: ridge; border-bottom-width: thin; border-bottom-color: Gray; } </style> <div data-role="header" data-theme="a"><h3 style="white-space:normal" data-backbtn="false"> Amrinone (Inocor) Pharmacology and Notes </h3></div> <p>Cardiac inotrope<br /> Vasodilator,<br /> Phosphodiesterase inhibitor</p> <p>Not as popular as Milrinone (Primacor) because Amrinone can causes thrombocytopenia.<br /> After intitial bolus with patients in CHF of 0.75-3mg/kg, dose related increases of cardiac output of 28-61% have been documented. </p> <p>Peak effect seen in 10 mins.</p> <hr/> <p><b>Indications</b>:Unresponsive CHF to conventional therapy</p> <hr/> <p><b>(150 mg ampl)<br /> Loading Dose:</b> </p> <p>0.75 mg/kg (in 2-3 min)<br /> Bolus doses can be administered undiluted. <br /> Repeat once in 30 minutes.<br /> <hr/> <b>Maintenance Dose:</b></p> <p>5-10 mcg/kg/min<br /> <hr/> <b>Dilution:</b></p> <p>200 mg in 250 ml bag of NaCl =(800mcg/mL)<b><br /> </b></p> <hr/> <p><b>Complications:</b> <br /> thrombocytopenia<br /> hypotension<br /> arrhythmias<br /> nausea<br /> vomiting<br /> hepatotoxicity<br /> Don't administer in same line with Lasix<br /> Don't dilute with glucose solutions,<br /> Hypersensitivity to bisulfites; <br /> Avoid concurrent use with disopyramide.</p> <hr> <p><b>Amrinone (Inocor) Notes</b></p> <hr/> <p><b>Class:</b></p> <p>Cardiac inotrope<br /> <hr/> <b>Actions:</b> </p> <p>A positive inotropic cardiotonic with vasodilator properties, phosphodiesterase inhibitory activity, and the ability to stimulate calcium ion influx into the cardiac cell. For patients with depressed myocardial function it increases cardiac output due to it<font face="Symbol">&#180;</font>s increasing contraction and vasodilator actions.<br /> Similar to dobutamine</p> <hr/> <p><b>Use:</b></p> <p>Management of patient with severe CHF that has not responded to diuretics, digitalis, and afterload reduction.<br /> <br /> Is effective even in fully digitalized patients<br /> It has been used concomitantly with other agents including digitalis, diuretics, and vasodilators<br /> <br /> </p> <hr/> <p><b>Indications:</b> </p> <p>Short-term management of severe CHF.<br /> Used during open heart surgery Management of patient with severe CHF that has not responded to diuretics, digitalis, and afterload reduction</p> <hr/> <p><b>Contraindications:</b> </p> <p>Patients with history of hypersensitivity to the drug. <br /> sensitivity to bisulfites, Amrinone contains sodium metabisulfite</p> <p>Pt with low Platelet count because it has shown to decrease platelet count in 2.4% of patients.<br /> Acute MI<br /> Excessive hypotension has been reported when amrinone was used concurrently with Disopyramide (Norpace) Should not be used in severe obstructive aortic or pulmonic valvular (inotropic agents, may aggravate outflow tract obstruction in conditions like hypertrophic subaortic stenosis). </p> <hr/> <p><b>Precautions:</b> <br /> May increase myocardial ischemia<br /> Only mix with NSS or 1/2 NS. Don��tmix with Dextrose solutions because it can precipitate.</p> <p>Don��t administer Lasix in the same line</p> <p>It also potentiates warfarin anticoagulation <br /> In patients Afib or Aflutter, digitalis should be given concomitantly to control the possible enhanced AV conduction induced by amrinone.</p> <hr/> <p><b>Side Effects:</b> </p> <p>Reduction in platelets, cardiac arrhythmias. Gastrointestinal Effects: nausea (1.7%), vomiting (0.9%), abdominal pain (0.4%), anorexia (0.4%) and diarrhea. <br /> <hr/> <b>Cardiovascular Effects</b>: </p> <p>Ventricular arrhythmias- vtachy, vfib, ventricular ectopy, SVT and bradycardia. </p> <hr/> <p><b>Dosage:</b> </p> <p>0.75 mg/kg bolus given slowly over 2-3 minute interval followed by maintenance infusion of 2-15 ��g/kg/minute. </p> <hr/> <p><b>Routes:</b> </p> <p>IV bolus and infusion as described earlier.</p> <p><b>Pediatric Dosage:</b> </p> <p>Safety in children has not been established.</p> <p>Pregnancy: There are no adequate studies in pregnant women. Amrinone should not be used during pregnancy unless the potential benefit to the patient justifies the potential risk to the fetus Protect from prolonged exposure to light</p> <hr/> <p><b>Half Life: </b></p> 5 to 8 hours <div data-role="footer" data-theme="a"><h4 style="white-space:normal"> </h4></div> </div> <!-- /page --> </body> </html>